Click any tag below to further narrow down your results
Links
Copenhagen startup BioinvestGPT runs virtual versions of drug trials with its AI models, and it says its forecasts were right in five of six cases so far. The companies behind these tools hope that testing drugs in simulation first will help more of them succeed in real human studies.
- BioinvestGPT shared its predictions for several high-profile drug trials with Reuters in July, before those results were public.
- The firm has been correct in five of six of those forecasts so far, a small sample that still needs more track record to judge.
- The pitch is that better virtual trials could cut the failure rate of expensive human studies.
The article argues that AI’s success in molecular design won’t cure most diseases without a deeper understanding of human biology and disease mechanisms. It calls for large-scale, causal biological measurements and better links between cellular data and clinical outcomes before AI can deliver truly transformative medicines.
- AI drug discovery has focused on molecule design, but the real bottleneck is upstream: most diseases lack a validated biological target to hit.
- 90% of clinical trials fail because they target the wrong biological mechanism, not because molecule design is too slow.
- Genuinely new drug targets have dropped from ~100 in 2015 to ~30 in 2024, while 38 targets each now have 50+ drug programs piling onto the same well-known locks.
- Fixing this requires massive causal/perturbational biology data (billions more measured cell states), not just better AI models, since current cell atlases barely scratch the surface.